NAS
VIR icon

Nykredit A/S’s Vir Biotechnology VIR Stock Holding History

Nykredit A/S’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Buy
+987
New +$9.39K ﹤0.01% 1872

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's VIR Position: Q2 2026 in Review

Nykredit A/S opened a new position in Vir Biotechnology (VIR) in Q2 2026: 987 shares worth $10.1K. The stake represents ﹤0.01% of the portfolio and ranks #1872 among its holdings.

155 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Nykredit A/S held 987 shares of Vir Biotechnology worth $10.1K as of Q2 2026.
  • Vir Biotechnology was a new Nykredit A/S position in Q2 2026.
  • Vir Biotechnology made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1872 holding.
  • 155 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.